Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Nivolumab

5

XVI.ab Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

1
Last update : 29/09/2017
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Avelumab
1
Durvalumab
3
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Lambrolizumab
4
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pembrolizumab
5

Publications

Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer.
American journal of respiratory and critical care medicine 2017 Nov 15;196;1349-1350 2017 Nov 15
Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment.
Lung cancer (Amsterdam, Netherlands) 2017 Jun;108;7-8 2017 Jun

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies